title: Influence of cytomegalovirus disease on early and late renal graft function.
abstract: The role of cytomegalovirus (CMV) disease to induce chronic nephropathy using new immunosuppressive regimens is debated. This study sought to assess the influence of CMV disease on early and late graft function in relation to immunosuppressive therapy. Among 456 renal recipients transplanted from 1997 to 2003, 95 were diagnosed with CMV disease on the basis of clinical symptoms and the presence of pp65 protein. The patients were divided into 2 groups according to their immunosuppressive regimen: group I included 43 patients treated with cyclosporine (CsA), azathioprine (AZA), and prednisone (P); group II, 52 patients treated with calcineurin inhibitor (CI), mycophenolate mofetil (MMF), and P. A control group of 90 CMV disease-free renal recipients were transplanted in 2001. CMV disease occurred in 20.8% of renal recipients: 14.8% from group I and 25.5% from group II. CMV disease was diagnosed in 73 patients (76.8%) before the third month after transplantation. An acute rejection episode (ARE) appeared in 42 patients, of whom 31 had CMV disease diagnosed within 1 month after ARE, while 5 before an ARE. In six patients ARE was not time related to CMV disease. The serum creatinine values at 6 months after transplantation were significantly higher among the CMV versus control groups: 1.69 and 1.76 vs 1.49 (P < .05). In patients with ARE and CMV disease, the serum creatinine value was also higher at 6 and 12 months after transplantation compared with patients without an ARE (P < .03). One- and 3-year graft survival rates were 95.1% and 83.7% in group I versus 93.4% and 86.5% in group II versus 95.4% and 90.2% in the control group. In conclusion, CMV disease showed a negative impact on early graft function independent of the immunosuppressive regimen, an effect that was emphasized by an ARE.
authors.affiliation: Department of Nephrology and Transplant Medicine, Wrocław Medical University, ul.Tragutta 57/59, 50-417 Wrocław, Poland. maria.boratynska@poczta.onet.pl
authors.forename: M
authors.initials: M
authors.lastname: Boratyńska
authors.forename: M
authors.initials: M
authors.lastname: Banasik
authors.forename: E
authors.initials: E
authors.lastname: Watorek
authors.forename: D
authors.initials: D
authors.lastname: Patrzałek
authors.forename: P
authors.initials: P
authors.lastname: Szyber
authors.forename: M
authors.initials: M
authors.lastname: Klinger
mesh_terms: D000328:Adult; D003586:Cytomegalovirus Infections / Q000209:etiology*; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology; D006650:Histocompatibility Testing; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000821:virology*; D012189:Retrospective Studies